Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84,213,667
-
Total 13F shares
-
8,407,168
-
Share change
-
-288,310
-
Total reported value
-
$78,583,000
-
Price per share
-
$9.05
-
Number of holders
-
17
-
Value change
-
-$2,815,272
-
Number of buys
-
3
-
Number of sells
-
3
Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q4 2018
As of 31 Dec 2018,
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,407,168 shares.
The largest 10 holders included
Vivo Capital, LLC, ORBIMED ADVISORS LLC, NEA Management Company, LLC, Abingworth LLP, venBio Partners LLC, venBio Partners L.P., Novo Holdings A/S, Aisling Capital Management LP, Tekla Capital Management LLC, and Foresite Capital Management III, LLC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.